Hyperthyroidism is a common condition with a global prevalence of 0· 2–1· 3%. When
clinical suspicion of hyperthyroidism arises, it should be confirmed by biochemical tests (eg …

Immune checkpoints are small molecules present on the cell surface of T-lymphocytes. They
maintain self-tolerance and regulate the amplitude and duration of T-cell responses …

Context Thyroid dysfunction occurs commonly following immune checkpoint inhibition. The
etiology of thyroid immune-related adverse events (irAEs) remains unclear and clinical …

Autoimmune toxicity occurs in up to 60% of patients treated with immune checkpoint inhibitor
(ICI) therapy for cancer and represents an increasing clinical challenge for expanding the …

Importance Growing research suggests that the prevalence of cutaneous immune-related
adverse events (cirAEs) is associated with favorable outcomes among individuals with …

Immune checkpoint inhibitor (ICI) immunotherapy leverages the body's own immune system
to attack cancer cells but leads to unwanted autoimmune side effects in up to 60% of …

Simple Summary Immune checkpoint inhibitors currently represent the standard of care for
the treatment of different tumor types and have also been proven to be effective in several …

Simple Summary With the growing use of immune checkpoint inhibitors (ICIs), clinicians are
increasingly encountering a unique set of adverse events called immune-related adverse …

Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events
including myocarditis, whilst improving cancer-related outcomes. There is thus a clinical …

Abstract Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become
the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC) …